Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor
- PMID: 10336509
Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor
Abstract
Previous findings in our laboratory suggested that the M1 muscarinic acetylcholine receptor (mAChR) agonist xanomeline exhibits a novel mode of interaction that involves persistent binding to and activation of the M1 mAChR, subsequent to extensive washout, as well as a possible insurmountable element. In the present study, we examined this interaction in greater detail, using Chinese hamster ovary cells transfected with the genes for the M1 mAChR and neuronal nitric oxide synthase. Pretreatment of cells with xanomeline, followed by extensive washout, resulted in elevated basal levels of neuronal nitric oxide synthase activity that were suppressed by the antagonists atropine or pirenzepine in a concentration-dependent manner. Analysis of the data yielded estimates of Schild slope factors and pKB values for the antagonists that were consistent with a model of simple competition between these latter agents and the persistently bound form of xanomeline. The ability of the antagonists to produce parallel dextral shifts of the concentration-response curves to carbachol and xanomeline was also investigated. The interaction between xanomeline and pirenzepine appeared to be insurmountable, but this may have been due to an equilibrium artifact. In contrast, the interaction between xanomeline and atropine conformed to a model of competition, indicating that the mode of interaction of free xanomeline at the M1 mAChR is pharmacologically identical with that of the persistently bound form. Radioligand binding studies also showed that the presence of various concentrations of xanomeline had no significant effect on the calculated affinity of atropine or pirenzepine in inhibiting the binding of [3H]N-methylscopolamine. Overall, these findings suggest that the persistent attachment of xanomeline to the M1 mAChR does not prevent this agonist from interacting with the classic binding site in a competitive fashion.
Similar articles
-
Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.CNS Drug Rev. 2003 Summer;9(2):159-86. doi: 10.1111/j.1527-3458.2003.tb00247.x. CNS Drug Rev. 2003. PMID: 12847557 Free PMC article. Review.
-
On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.Mol Pharmacol. 1998 Jun;53(6):1120-30. Mol Pharmacol. 1998. PMID: 9614217
-
Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors.Br J Pharmacol. 1998 Dec;125(7):1413-20. doi: 10.1038/sj.bjp.0702201. Br J Pharmacol. 1998. PMID: 9884068 Free PMC article.
-
Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor.Neurosci Lett. 2006 Dec 13;410(1):11-4. doi: 10.1016/j.neulet.2006.09.062. Epub 2006 Oct 18. Neurosci Lett. 2006. PMID: 17052840 Free PMC article.
-
From 'captive' agonism to insurmountable antagonism: demonstrating the power of analytical pharmacology.Clin Exp Pharmacol Physiol. 2001 Mar;28(3):223-9. doi: 10.1046/j.1440-1681.2001.03376.x. Clin Exp Pharmacol Physiol. 2001. PMID: 11236130 Review.
Cited by
-
Bispyridinium Compounds Inhibit Both Muscle and Neuronal Nicotinic Acetylcholine Receptors in Human Cell Lines.PLoS One. 2015 Aug 14;10(8):e0135811. doi: 10.1371/journal.pone.0135811. eCollection 2015. PLoS One. 2015. PMID: 26274808 Free PMC article.
-
Allosteric modulators of class B G-protein-coupled receptors.Curr Neuropharmacol. 2007 Sep;5(3):168-79. doi: 10.2174/157015907781695928. Curr Neuropharmacol. 2007. PMID: 19305799 Free PMC article.
-
N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport.Br J Pharmacol. 2001 Dec;134(7):1429-36. doi: 10.1038/sj.bjp.0704381. Br J Pharmacol. 2001. PMID: 11724748 Free PMC article.
-
Pharmacological evaluation of the long-term effects of xanomeline on the M(1) muscarinic acetylcholine receptor.PLoS One. 2010 Dec 23;5(12):e15722. doi: 10.1371/journal.pone.0015722. PLoS One. 2010. PMID: 21203415 Free PMC article.
-
Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.CNS Drug Rev. 2003 Summer;9(2):159-86. doi: 10.1111/j.1527-3458.2003.tb00247.x. CNS Drug Rev. 2003. PMID: 12847557 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Miscellaneous